#Securities Fraud #Pomerantz Law #Regencell Bioscience

Pomerantz Law Firm Launches Class Action Against Regencell Bioscience Holdings

The renowned Pomerantz Law Firm has officially filed a class action lawsuit against Regencell Bioscience Holdings Limited, a NASDAQ-listed company, along with several individuals from its management team. The case, which is being heard in the U.S. District Court for the District of Maryland, is set under docket number 26-cv-01602.

This class action is particularly aimed at benefiting all investors who purchased or otherwise acquired securities from Regencell during the specified class period from October 28, 2024, to October 31, 2025. The lawsuit seeks to unveil and rectify the damages stemming from the alleged violations of federal securities laws orchestrated by the defendants. Investors who wish to lead the class action must file their motions by June 23, 2026. Further details and the full complaint are accessible through Pomerantz Law's official website.

Allegations Against Regencell

Regencell is known for its focus on the innovative utilization of Traditional Chinese Medicine (TCM) aimed at treating conditions such as attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The company proclaims that its treatments aim at addressing the root causes of these neurocognitive disorders rather than just alleviating symptoms. However, the class action raises serious concerns about the company’s operational transparency and disclosures related to its financial health and stock performance.

Throughout the class period, Regencell's shares were reportedly traded at less than 30 cents each, but this drastically changed in early May 2025 when the share price surged unexpectedly to a peak of $78.00 on June 17, representing an astonishing increase of 48,650%. Surprisingly, subsequent to this spike, the stock price dwindled swiftly, averaging between $27.00 and $29.00 as of the lawsuit's filing.

These fluctuations prompted questions about potential market manipulation and the integrity of disclosures made by the company. Regencell has been characterized as a